Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas receives positive CHMP opinion in IgA nephropathy

Interim Report Q1, 2022

Number of shares and votes in Calliditas Therapeutics

Calliditas Therapeutics’ 2021 Annual Report Published

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Year-End Report, 2021

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2022